Avanos Medical, Inc.

NYSE:AVNS

Medical - Devices

Healthcare
$24.99 +0.22%

+$0.06 today

Market cap
$1.17B
Beta
1.57
P/E (TTM)
-16.7
EPS (TTM)
-$1.50
52W Low $9.30High $25.49

Volume 0.43M

Average 1.49M

AVNS Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Avanos Medical, Inc.NYSE: AVNS

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$774.8M, compared with -$700.4M a year earlier.

Context

  • Retained earnings amounted to 73.8% of total assets at the end of Q1 FY2026, up 10.6 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -10.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$774.8M+0.7% QoQ
Last fiscal yearDec 2025
-$779.9M-10.3% YoY
Year agoMar 2025
-$700.4M-10.6% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.6%——
1 year-10.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(779.9M) USD
Year-over-year change
-10.3%

Retained Earnings vs competitors

How AVNS compares with its peers on the latest reported figures

  • AVNS's Mar 2026 retained earnings of -$774.8M is the 6th highest of the 11 companies compared; the peer median is -$558.44M.
  • Its year-over-year change of -10.6% is the 5th highest of 11, against a peer median of -20.3%.
  • Retained earnings amounts to 73.8% of total assets for AVNS, versus a peer median of 141.0%.
AVNS Competitors Peer median
Retained Earnings for AVNS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VREXVarex Imaging CorporationApr 2026-$11.7M -115.2%—1.1%
CTKBCytek Biosciences, Inc.Mar 2026-$120.6M -158.8%—26.9%
CLPTClearPoint Neuro, Inc.Mar 2026-$226.46M -14.7%—242.4%
CBLLCeriBell, Inc.Mar 2026-$240.09M -33.6%—134.8%
BVSBioventus Inc.Mar 2026-$331.82M +7.9%—51.0%
AVNSAvanos Medical, Inc.Mar 2026-$774.8M -10.6%—73.8%
FDMT4D Molecular Therapeutics, Inc.Mar 2026-$785.06M -25.8%—153.1%
BCYCBicycle Therapeutics plcMar 2026-$960.58M -29.5%—147.2%
LABStandard BioTools Inc.Mar 2026-$1.13B +6.5%—177.4%
PACBPacific Biosciences of California, Inc.Mar 2026-$2.7B -5.0%—345.6%
CYHCommunity Health Systems, Inc.Mar 2026-$3.63B +11.4%—27.5%
Peer median (excluding AVNS) -$558.44M-20.3%—141.0%

Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents118.5M127.7M87.7M107.7M89.8M
Short-term Investments00000
Net Receivables131.2M167.9M142.8M132.8M103.8M
Inventory159.3M132.3M163.2M138.8M148M
Other Current Assets0196.2M93.3M14.1M13.8M
Total Current Assets427.6M624.1M487M393.4M355.4M
Property, Plant & Equipment (Net)206.7M146.1M144M144.8M141M
Goodwill801.6M760.3M796.1M455.6M394.9M
Intangible Assets141.2M234.2M239.5M112.3M117.8M
Long-term Investments00000
Tax Assets10M4.6M6.5M24.9M33.1M
Other Non-current Assets16.5M17.6M19.3M23.2M31.5M
Total Non-current Assets1.18B1.16B1.21B760.8M718.3M
Total Assets1.6B1.79B1.69B1.15B1.07B
Account Payables56.4M67.9M56.3M54.3M55.5M
Short-term Debt14.7M6.2M8.6M9.4M10.2M
Tax Payables3M21.2M16.7M18M0
Deferred Revenue00000
Other Current Liabilities35.8M7.1M108.7M73.3M0
Total Current Liabilities139.2M191M234.6M165.9M165.2M
Long-term Debt130M226.3M159.4M125.3M90.3M
Deferred Tax Liabilities11.9M25.4M23.8M5.5M6.1M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities9.1M20.5M10M4.4M13.5M
Total Non-current Liabilities193.8M304.7M221.5M159.8M130.3M
Total Liabilities333M495.7M456.1M325.7M295.5M
Common Stock500K500K500K500K500K
Retained Earnings(303.6M)(253.1M)(314.9M)(707M)(779.9M)
Accumulated OCI(33.8M)(35.8M)(27M)(44.6M)(32M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.27B1.29B1.24B828.5M778.2M
Total Debt187.5M277M209.1M170.2M129.1M
Net Debt69M149.3M121.4M62.5M39.3M

Avanos Medical, Inc.

NYSE:AVNS

Intrinsic Alpha fair value

Locked

Current Price

$24.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.